Metastatic Melanoma in the breast BRAF Positive in Albino Patient
DOI:
https://doi.org/10.29176/2590843X.1673Keywords:
Albinism; Melanoma; Metastasis to the breastAbstract
Melanoma is the skin tumor with the highest mortality. Light-skinned people with a skin phototype are more likely to develop melanoma. However, in albine patients, it is an infrequent finding. It is easy to metastasize, but the breast is a rare site of metastasis.
The objective is to report a case diagnosed with metastatic melanoma in the breast associated with the BRAF mutation gene in a patient with oculocutaneous albinism for treatment of two infrequent conditions (albinism and metastasis in the breast of a melanoma). We present a case of a 52-year-old female patient with the characteristics described above and a BRAF gene mutation, describing her presentation, diagnosis, and treatment
References
Reato Marc CR¸ Maia M Albinism: epidemiology, genetics, cutaneous characterization, psychosocial factors. A bras dermatol.2019;94(5):503-520 https://doi.org/10.1016/j.abd.2019.09.023
Emadi SE, Juma Suleh A, Babamahmoodi F, Ahangarkani F,Betty Chelimo V, Mutai B, et al. Common malignant cutaneous conditions among albinos in Kenya. Med J Islam Repub Iran. 2017;31:3 Disponible en http://doi.org/10.18869/mjiri.31.3
NCCN Clinical Practice guidelines in oncology (NCCN guidelines) melanoma version 2.2020, disponible en: http://www.nccn.org
Ribas A, Read P, Craig L. Cutaneous melanoma. En: Principles practices of Oncology. De Vita Jr. VT, Hellman S, Rosenberg SA (edt)11 th edition. Philadelphia, EUA: Wolters Kluwer 2019, pp 2674-2744
Abrams HL, Spiro R, Goldstein N. Metastases in carcinoma; analysis of 1000 autopsied cases. Cancer. 1950;3(1):74-85. https://doi.org/10.1002/1097-0142(1950)3:1%3C74::aid-cncr2820030111%3E3.0.co;2-7
Long GV, Eroglu Z, Infante J. Long-term outcomes in patient with BRAF V600 mutant metastasic melanoma who received dabrafenib combined with trametinib. J Clin Oncol 2018; 36:667-673 https://doi.org/10.1200/JCO.2017.74.1025
Chapman PB, Robert C, Larkin J, et al. Vemurafenib in patients with BRAFV600 mutation-positive metastatic melanoma: final overall survival results of the randomized BRIM-3 study. Ann Oncol 2017;28(10):2581-7 https://doi.org/10.1093/annonc/mdx339
Ascierto PA, McArthur GA, Dreno B, et al. Cobimetinib combined with vemurafenib in advanced BRAF(V600)-mutant melanoma (coBRIM): updated efficacy results from a randomised, double-blind, phase 3 trial. Lancet Oncol 2016;17(9):1248-60. https://doi.org/10.1016/S1470-2045(16)30122-X
De Suma S, Guida M, Toammasi S, Strippoli S, Pellegrini C, fargnoli MC. Genetic profiling of a rare condition:co-ocurrence of albinism and multiple primary melanoma in a caucasian family. Oncotarget, 2017;8(18):29751-9. https://doi.org/10.18632/oncotarget.12777
Camacho Limas CP, Gerson Cwilich R, Góngora Jurado MA, Villalobos Prieto A, Blanco Vázquez YC, López Riverol O. Actualidades para el tratamiento del melanoma metastásico. An Med (Mex) 2017; 62(3):196-207.
How to Cite
Downloads
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2022 Revista de la Asociación Colombiana de Dermatología y Cirugía Dermatológica
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.
| Article metrics | |
|---|---|
| Abstract views | |
| Galley vies | |
| PDF Views | |
| HTML views | |
| Other views | |
